We advised the underwriters on the offering

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered debt offering by Merck & Co., Inc. of $6 billion aggregate principal amount of notes. The notes were offered in seven tranches, including floating-rate notes maturing in 2028 and fixed-rate notes maturing in 2028, 2031, 2033, 2036, 2046 and 2056.

Merck is a global healthcare company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its operations are principally managed on a product basis and include two operating segments, pharmaceutical and animal health.

The Davis Polk capital markets team included partner Stephen A. Byeff and associate Raphaelle Desaleux. The tax team included counsel Tracy L. Matlock and associate Valentin Van de Walle. All members of the Davis Polk team are based in the New York office.

Copy link to share post